The future of CAR-T cell therapy focuses on refining its design to treat a broader range of cancers, including the development of “universal” CAR-T cells that bypass patient-specific MHC dependence, enabling off-the-shelf therapies for faster deployment. The gene discussed is HLA-C; the disease is cancer.